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GENE THERAPY
Promoter trapping reveals significant differences in integration site selection
between MLV and HIV vectors in primary hematopoietic cells
Michele De Palma, Eugenio Montini, Francesca R. Santoni de Sio, Fabrizio Benedicenti, Alessandra Gentile, Enzo Medico, and Luigi Naldini
Recent reports have indicated that hu-
man immunodeficiency virus (HIV) and
murine leukemia virus (MLV) vectors
preferentially integrate into active genes.
Here, we used a novel approach based
on genetic trapping to rapidly score
several thousand integration sites and
found that MLV vectors trapped cellular
promoters more efficiently than HIV vec-
tors. Remarkably, 1 in 5 MLV integrations
trapped an active promoter in different
cell lines and primary hematopoietic
cells. Such frequency was even higher
in growth-stimulated lymphocytes. We
show that the different behavior of MLV
and HIV vectors was dependent on a
different integration pattern within tran-
scribed genes. Whereas MLV-based
traps showed a strong bias for promoter-
proximal integration leading to efficient
reporter expression, HIV-based traps in-
tegrated throughout transcriptional
units and were limited for expression by
the distance from the promoter and the
reading frame of the targeted gene. Our
results indicate a strong propensity of
MLV to establish transcriptional interac-
tions with cellular promoters, a behav-
ior that may have evolved to enhance
proviral expression and may increase
the insertional mutagenesis risk. Pro-
moter trapping efficiency provides a
convenient readout to assess transcrip-
tional interactions between the vector
and its flanking genes at the integration
site and to compare integration site
selection among different cell types and
in different growth conditions. (Blood.
2005;105:2307-2315)
© 2005 by The American Society of Hematology
Introduction
Integration of a transgene into the cell chromatin may ensure stable
expression of the gene product in the target cell and its progeny.
Because of this feature, integrative vectors, such as retrovirus-
based vectors, have been the preferred choice for gene delivery into
hematopoietic cells, including lymphocytes, hematopoietic progeni-
tors (HPCs), and hematopoietic stem cells (HSCs). However, the
occurrence of adverse events consequent to vector integration in an
otherwise successful human gene therapy trial has prompted a
reassessment of the insertional mutagenesis risk by retroviral
vectors.1-4 In one X-linked severe combined immunodeficiency
trial, 2 patients developed a leukemia-like syndrome after transplan-
tation with gamma-retrovirus–transduced HSCs.2,5 In both leuke-
mic clones, the gamma-retroviral vector (RV) integrated close to
the promoter of a proto-oncogene and up-regulated its expression.
Recent reports have challenged the notion that retroviral integra-
tion occurs randomly in the target cell genome and indicated
specific biases for integration into transcriptionally active genes
both for murine leukemia virus (MLV)– and HIV-based vectors.6-8
Better understanding and comparative analysis of integration site
selection among different integrating vectors are thus critically
needed to properly evaluate the risk-benefit ratio in gene therapy
applications and to develop safer vectors. Toward these aims,
several groups have engaged in high-throughput retrieval of vector
integration sites. Here, we describe a complementary approach,
based on promoter traps, that allows quantitative and comparative
assessment of some vector-specific integration biases by probing
hundred thousand integrations at once in different types of target
cells, including primary cells tested in different conditions, with a
simple, cost-effective procedure.
By comparing cells carrying equal amounts of integrated
vectors, we show that MLV vectors trapped cellular promoters
much more efficiently, and likely targeted more active genes, than
HIV vectors. By comparing the average transcript length of MLV
and HIV traps and by modifying the trap design to make it
independent of the reading frame of the targeted gene, we show
that the observed differences between MLV and HIV vectors
were due to a different integration pattern within transcribed
genes. Expression of MLV-based traps was highly efficient
because of a strong bias for promoter-proximal integration.
Expression of HIV-based traps, however, was limited by the
distance from the promoter and the reading frame of the targeted
gene because the vector integrated throughout the transcrip-
tional unit. The different mechanism of expression of MLV- and
HIV-based traps was confirmed by mapping the integration site
in selected reporter-expressing cells. These results, obtained in
different types of cell lines and primary cells, highlighted the
propensity of MLV to establish transcriptional interactions with
cellular promoters, a behavior that may have evolved to enhance
proviral expression, and which likely increases the risk associ-
ated with insertional mutagenesis.
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Materials and methods
Generation of HIV-based and MLV-based promoter traps
A puromycin resistance–green fluorescent protein (PuroR-GFP) fusion gene
was cloned into the promoter trap pROSA-GFNR9 in place of GFNR.PGK-
neo, and the resulting expression cassette (Splice Acceptor site.PuroR-
GFP.polyA) was excised by AflII/NheI digestion and cloned in reverse
orientation into the HIV-based self-inactivating (SIN) lentiviral vector
pRRL.SIN.cPPT.PGK.GFP in place of PGK.GFP or into the MLV-based
SIN retroviral vector pRkat43.3.PGK.YFP10 in place of PGK.YFP to
generate lentiviral trap (LT) and retroviral trap (RT) vectors, respectively.
The encephalomyocarditis virus internal ribosome entry site (IRES)
element11 was polymerase chain reaction (PCR)–amplified from plasmid
pRRL.sin.PPT.CMV.Luciferase.IRES-EMCVwt.GFP.wPRE12 using oligo-
nucleotides designed to add stop codons in all 3 reading frames in the 5
portion of the element. The resulting PCR product was in-frame cloned
upstream to the PuroR-GFP fusion protein. The woodchuck posttranscrip-
tional regulatory element (wPRE)13 was cloned downstream to the PuroR-
GFP cDNA. The resulting expression cassettes were cloned into the
HIV-based and the MLV-based vectors to generate IRES-, wPRE-, and
IRES.wPRE-LT and -RT. The HIV-based pRRL.SIN.cPPT.PGK.GFP.
wPRE14 lentiviral (L) and the MLV-based pRkat 43.3.PGK.GFP retroviral
(R) vectors were used as controls.
Vesicular stomatitis virus (VSV)–pseudotyped vector stocks were
produced by transient cotransfection of the selected transfer vector con-
struct, the packaging construct pCMVR8.74 (for HIV-based vectors) and
pCMV.GAG.POL (for MLV-based vectors), and the pMD2.G construct in
293T cells and concentrated hundred-fold by ultracentrifugation as previ-
ously described.14 Vector stocks were titered on 293T cells by integration
titer, end-point green fluorescent protein (GFP) and PuroR expression titer,
as previously described.15 Briefly, vector integration titers were calculated
measuring the vector DNA content of transduced in reference to known
standards, such as a curve of plasmid DNA or cell clones carrying known
amounts of integrated vector, by Southern blot, or real-time PCR analysis,
or both. For Southern blot, the DNA was digested with AflII, which excises
a fragment containing the reporter gene from each vector type. Real-time
PCR analysis was performed as previously described16 using oligonucleo-
tides and probe complementary to the GFP sequence common to all vector
types (forward primer, 5-CAGCTCGCCGACCACTA-3; reverse primer,
5-GGGCCGTCGCCGAT-3; 6-carboxylfluorescein [FAM] reporter probe,
5-CCAGCAGAACACCCCC-3; Applied Biosystem, Foster City, CA).
Integration titers were in the range of 108 to 109 vector copies/mL
(transducing units293T/mL) for all vector types. GFP expression titers were
calculated from the frequency of GFP-positive cells by fluorescence
activated cell sorting (FACS) analysis of cultures transduced with high
dilutions of vector stocks. PuroR expression titers were determined by
plating transduced cells at different dilutions in medium containing 1
g/mL puromycin and scoring colonies after 1 to 2 weeks by crystal
violet staining.
Transduction of cell lines
293T, MLP29, and H5V cells were maintained in Iscove modified Dulbecco
medium (IMDM; Sigma Chemical, Milan, Italy) with 10% fetal bovine
serum (FBS; Gibco BRL, Grand Island, NY) and glutamine. Cells were
transduced with normalized amounts of the different vectors to obtain equal
levels of integration and grown for at least 4 days before FACS analysis to
reach steady-state PuroR/GFP expression. Selection of puromycin-resistant
cells was performed by using 1 g/mL puromycin for 5 to 14 days.
Transfection of linear plasmid forms of vector traps
Linear plasmid forms (0.2, 1, and 2 g) of both HIV and MLV traps,
spanning from the 5 to the 3 long terminal repeat (LTR), were prepared by
AflIII/SfiI digestion and transfected into 293T cells by calcium-phosphate
DNA precipitation. Transfectants were analyzed for GFP expression 3 days
later or cultured in medium containing 1 g/mL puromycin for 1 week and
scored for colony growth by crystal violet staining.
Mapping of trap integration sites
Integration site mapping was performed on DNA extracted from puromycin-
resistant 293T cells. The genomic-proviral junction sequence was identified
using linear amplification-mediated (LAM)–PCR, as previously de-
scribed17 (using the following biotinylated primer for the retroviral trap:
5-CGACCCTGTTCCATCTGTTCCTGACC-3). PCR products were
cloned into pCR2.1-TOPO (Invitrogen, Carlsbad CA) and sequenced.
Sequences of LAM-PCR products were mapped using BLAST (basic local
alignment search tool) analysis against the human genomic sequence at the
ENSEMBL database (September 2004 freeze).
Transduction of primary hematopoietic cells
Cells from human subjects were obtained with informed consent according
to the Declaration of Helsinki. Peripheral blood mononuclear cells (PBMCs)
were isolated from healthy donors according to a protocol approved by the
H. San Raffaele Bioethical Committee by leukophoresis and Lymphoprep
gradient separation (Axis-Shiel PoC AS, Oslo, Norway), stimulated for 2
days with anti-CD3 (1 g/mL) and anti-CD28 (0.5 g/mL) antibodies (both
from DAKO, Glostrup, Denmark) and phytohemagglutinin (1 g/mL), and
grown in RPMI with 5% human serum (Sigma) at 1 106 cells/mL in the
presence of human recombinant interleukin 2 (IL-2; 10 U/mL; EuroCetus
Italia S.r.l., Milan, Italy). Activated cells were transduced using 106 and 107
transducing units293T/mL vector. Cells were analyzed by FACS 1 week after
transduction or cultured in the presence of puromycin (2 g/mL) for an
additional week before FACS analysis.
Bone marrow was harvested from femurs and tibias of 6-week-old
C57Bl/6 mice. Hematopoietic progenitors were isolated using a kit
(StemCell Technologies, Vancouver, Canada) and stimulated for 24 hours
with 20 ng/mL recombinant mouse (rm)–IL-3, 100 ng/mL rm–stem cell
factor (SCF), rm– FMS-like tyrosine kinase 3 (FLT-3) ligand, and
rm-thrombopoietin (TPO), all from PeproTech (Rocky Hill, NH) in
StemSpan serum-free medium (StemCell Technologies). Cells (106/mL)
were transduced using 5 107 transducing units293T/mL.
Mononuclear cells were obtained from human cord blood scheduled for
discard according to a protocol approved by the H. San Raffaele Bioethical
Committee, by gradient centrifugation over Lymphoprep, and CD34 cells
were isolated using the Miltenyi magnetic cell sorting (MACS) kit
(Miltenyi Biotec, Gladbach, Germany) and stimulated for 36 hours with 20
ng/mL recombinant human (rh)–IL-6, 100 ng/mL rh-SCF, 100 ng/mL
rh-FLT-3 ligand, and 20 ng/mL rh-TPO, all from PeproTech, in StemSpan
serum-free medium,17 before transduction with 107 transducing units293T/
mL. For liquid cultures, cells were maintained in medium containing 20
ng/mL rh–IL-6, 100 ng/mL rh-SCF, and 20 ng/mL rh–IL-3, all from
PeproTech, for 7 days before analysis. For puromycin selection, puromycin
(1 g/mL) was added to the medium 3 days after transduction. For FACS
analysis, cells were stained with propidium iodide (PI) and analyzed by
FACS. Only viable, PI-negative cells were used for the analysis. Colony-
forming cell (CFC) assays and GFP-specific PCR were performed as
previously described.17 For scoring puromycin-resistant CFCs, cells were
plated 24 hours after transduction on methylcellulose-based medium
(StemCell Technologies), with or without 1 g/mL puromycin.
Results
MLV vectors trap cellular promoters more efficiently than HIV
vectors in target cell lines
We introduced a promoter trapping construct9 into HIV and MLV
vectors and compared their trapping efficiency by using a puromy-
cin resistance-GFP (PuroR-GFP) reporter. We cloned the PuroR-
GFP gene between a strong cellular splice acceptor (SA) and a
polyadenylation (polyA) site9 and inserted the resulting expression
cassette in reverse orientation into SIN MLV10 and HIV14 vectors,
immediately upstream to the modified 3 LTR (Figure 1A). The
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reverse orientation prevents reporter expression from the 5 LTR of
the transduced vector when the LTR is not fully inactivated, as in
the case of the SIN MLV vector (described in Figure 2). Reporter
expression is dependent on vector integration downstream to a
transcriptionally active cellular promoter. If the vector integrates
with the appropriate orientation within a promoter-proximal intron
or exon of a transcribed gene, a fusion messenger transcript will be
produced that is likely to be processed to express the reporter. The
placement of the expression cassette close to the 3 end of the
vector leaves most viral sequences outside of the fusion
transcript, reducing their potential influence on reporter expres-
sion. The frequency and average level of reporter expression
may thus read out the frequency of vector integration into active
genes, their average expression level, and may uncover preferen-
tial integration in the proximity of cellular promoters. If target
site selection differs between MLV and HIV according to these
parameters, it will also result in quantifiable differences in their
promoter trapping efficiency.
We transduced human 293T cells with VSV-pseudotyped stocks
of each vector trap and of control standard vectors expressing GFP
from an internal phosphoglycerate kinase promoter. Whereas the
control MLV and HIV vectors expressed the reporter gene to
similarly high efficiency, with expression titers approaching integra-
tion titers,15 we observed significant differences between the 2
types of trapping vector. By analyzing cell populations containing
similar amounts of integrated vector, we found that promoter
trapping efficiency, calculated as the ratio between expression and
integration, was significantly higher (4- to 5-fold) for the MLV than
the HIV trap (Figure 1B). In this and other experiments, integration
was measured in transduced cells by Southern analysis or real-time
PCR using a probe specific for the GFP sequence contained in all
types of constructs. Trapping efficiency was calculated from
cultures expressing the reporter gene in less than 20% of the cells to
avoid the possibility that multiple trapping events per cell led to
nonlinear dose-response between integration and expression. In 6
independent experiments, promoter trapping efficiency was
20% 3% for the MLV trap and 5% 1% for the HIV trap with a
highly significant statistical difference (P  .005). We reproduced
these findings in murine cell lines, such as liver progenitor MLP29
cells (Figure 1C) and endothelial H5V cells. In the latter cells,
trapping efficiency was 17% 2% for the MLV trap and 5%  2%
for the HIV trap (P  .05).
Remarkably, the expression titer of the MLV trap was on
average only 5-fold lower than its integration titer, indicating that 1
of 5 integrations occurred downstream to a transcriptionally active
promoter and led to reporter expression in the cells tested.
Intriguingly, the mean fluorescence intensity (MFI) of GFP was
higher in transduced cells expressing the MLV trap (1.6-fold on
average in 293T cells, n 6, P  .05) as compared with cells
expressing the HIV trap. This difference was maintained after
puromycin selection of the trap-expressing cells (Figure 1C).
A possible explanation for these findings was that the MLV
vector framework was more permissive to gene expression follow-
ing integration than the HIV one, either because the 3 LTR and
flanking sequences enhanced expression of the fusion messenger or
because of the residual promoter activity in the 5 LTR. The latter,
however, drives antisense transcription of the reporter cassette and
may thus inhibit rather than promote its expression. To investigate
this point, we transfected linear plasmid forms of both vector traps,
spanning the distance from the 5 to the 3 LTR, into 293T cells by
calcium-phosphate DNA precipitation. By this approach, insertion
of the vector DNA into the target cell chromatin occurs by the
cellular recombination machinery, thus independently from the
viral proteins that govern the efficient integration of retroviral
genomes. As in the case of viral delivery, expression of the reporter
gene was dependent on vector DNA insertion downstream to an
active promoter. Contrary to the findings observed after viral
transduction, we found that the trapping efficiencies of the trans-
fected MLV and HIV traps were not statistically different (P  .6;
Figure 1. Transduction of 293T and MLP29 cells by HIV-based lentiviral (LT) and
MLV-based retroviral (RT) promoter traps. (A) A schematic of the vector trap
integrated within the first intron of a cellular gene. The expression cassette is placed
in reverse transcriptional orientation with respect to the vector framework.	 indicates
viral encapsidation signal, including the 5 portion of gag gene (GA); RRE, rev
responsive element, cPPT, central polypurine tract (LT only); polyA, polyadenylation
signal; SD and SA, splice donor and acceptor sites. (B, left) Southern blot analysis of
293T cells transduced with LT, RT, MLV-based retroviral vector (R), and HIV-based
lentiviral vector (L). Matched vector amounts were used that yielded an average of 1
integrated vector copy per cell. A standard curve of plasmid DNA was used to
calculate the vector copy-number. DNA was digested with AflII and the filter probed
for puromycinR-GFP sequences. (Right) FACS analysis (dot plot) of GFP expression
in transduced cells. The percentage and mean fluorescence intensity (MFI) of
GFP-positive cells, and the vector copy-number per cell (calculated by Southern
blot), are indicated for each cell culture. (C) FACS analysis of GFP expression in
MLP29 cells transduced with the indicated traps and left untreated (dot plots on the
left; the MFI of GFP-positive cells is indicated) or treated with puromycin (dot plots on
the right, and histograms; the MFI of the total population is indicated). UC indicates
untransduced untreated cells. (D) FACS analysis (dot plot) of 293T cells transfected
with the indicated amounts of linear plasmid forms of each vector trap. The results
shown are representative of at least 3 experiments performed.
INTEGRATION SITE SELECTION BY MLV AND HIV VECTORS 2309BLOOD, 15 MARCH 2005  VOLUME 105, NUMBER 6  For personal use only.2012. 
 at ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE on June 15,bloodjournal.hematologylibrary.orgFrom 
Figure 1D and other data not shown). These results indicated that
the higher promoter trapping efficiency observed for the MLV trap
after transduction was dependent on the retroviral integration
machinery and not on differences in the vector backbone. The
higher GFP MFI observed for HIV traps as compared with MLV
traps after DNA transfection suggested that, in the absence of viral
components affecting integration site selection, the HIV trap was
even slightly more permissive to reporter expression than the latter,
possibly because of the complete absence of antisense transcription
from the vector 5 LTR. Taken together, infection and transfection
experiments indicated that the MLV mechanism of integration
specifically favored promoter trapping and suggested that it
preferentially targeted more active genes than those targeted by
HIV vectors.
A bias for promoter-proximal integration accounts for the high
promoter trapping efficiency of MLV vectors
We analyzed reporter expression in 293T cells transduced with
matched amounts of each vector trap by Northern blot (Figure 2).
Consistently with the protein expression data, the hybridization
signal was much weaker in cells transduced by the HIV trap than in
cells transduced by the MLV trap. In addition, the HIV-derived
transcripts displayed a much wider size range as compared with
MLV-derived transcripts. The majority of MLV-derived transcripts
did not exceed 2 kb in length, except for a distinct 4-kb band,
representing the transcript originating from the 5 LTR. Since the
reporter transcript encompasses approximately 1.8 kb of vector
sequence, these results showed that the large fraction of MLV
integrations resulting in reporter expression (1 of 5) occurred in
close proximity to the transcription start site of active genes. Such a
strong bias for promoter-proximal insertion within active transcrip-
tion units represents an advantage for promoter trapping, since
lengthy fusion mRNAs originating from promoter-distal insertions
are unlikely to express the reporter protein. Interestingly, Northern
analysis of transduced cells, performed after puromycin selection,
showed strong enrichment in HIV-derived transcripts of similar
size as that observed for the MLV traps, indicating that the fraction
of HIV integrations resulting in efficient reporter protein expres-
sion were those occurring proximal to a promoter or within the first
intron. The average reporter expression level of these 2 cell
populations, selected for similar placement of the reporter cassette
within the transcription unit, remained higher for MLV traps,
further suggesting that, on average, MLV vectors targeted more
active genes than those targeted by HIV vectors within the
same cells.
We then isolated a panel of HIV and MLV trap clones by
puromycin selection and found by Northern analysis that they were
representative of the 2 parental bulk-selected cell populations
(Figure 2). We retrieved the vector-genome junction from the
puromycin-selected populations and clones by LAM-PCR18 and
mapped the integration site on the human genome by BLAST
analysis using the ENSEMBL search engine (September 2004
freeze). A list of the mapped integration sites for both types of
vector is shown in Table 1. Representative examples of vector
orientation and placement within the targeted loci are shown in
Figure 3.
Concerning HIV integrations, 6 of 10 insertions occurred within
the first intron of an identified gene, with the trap inserted in the
proper orientation for reporter expression. These data provided
experimental evidence that selection for reporter expression strongly
enriched for HIV integrations occurring within the first intron of an
expressed gene. Notably, the distance of these integrations from the
transcription start site (TSS) ranged from 3 to 24 kb, in sharp
contrast with MLV integrations that were clustered close to the
promoter. Three insertions were mapped within known transcrip-
tion units but apparently in the wrong orientation for expression.
Searching of EST databases revealed natural antisense transcripts
(NATs19) for these loci, providing a possible mechanism of reporter
expression.
Concerning MLV integrations, 8 of 10 mapped sites occurred in
close proximity ( 1.5 kb) to established or putative transcriptional
promoter regions, as identified by the upstream location to a
RefSeq transcript, the content of CpG islands, Eponine and FirstEF
annotations for putative promoter/transcription start sites.20 These
data strongly supported the proposed mechanism that promoter-
proximal integration accounted for the high promoter trapping
efficiency by the MLV vector.
MLV vectors trap cellular promoters more efficiently than HIV
vectors in primary hematopoietic cells
We compared the behavior of MLV and HIV vector traps in a panel
of hematopoietic cells representing relevant targets for gene
therapy. Human PBMCs were activated by phytohemagglutinin
(PHA) and anti-CD3/anti-CD28 treatment for 2 days, transduced
with 2 matched doses of HIV and MLV traps, and analyzed for GFP
expression by FACS analysis and for vector integration by
real-time PCR 7 to 10 days later. As shown in Table 2, the HIV trap
integrated into the chromatin of PBMCs with higher efficiency than
the MLV trap, as expected after a single round of infection with
these 2 types of vectors. However, MLV trapping efficiency was on
average 4 times higher than that of HIV (P  .01). Remarkably, up
to 37% of integrated MLV traps expressed the reporter gene in
these target cells. As seen with continuous cell lines, the GFP MFI
after puromycin selection was higher for the MLV than the HIV
trap (1.3-fold; P  .05).
We then analyzed the behavior of the traps in HPCs. Murine
HPCs were enriched from bone marrow cells by lineage marker
depletion, stimulated with a combination of cytokines for 24 hours
to reach efficient transduction by both vector types, and transduced
with doses of HIV and MLV traps matched to yield comparable
vector integration amounts (not shown). FACS analysis performed
after 5 days of culture indicated a sharp difference in reporter gene
expression, with the cultures transduced by the MLV trap contain-
ing a higher frequency of GFP-expressing cells and reaching a
higher GFP MFI (Figure 4A).
Human HPCs were purified from cord blood by CD34
selection and stimulated for 36 hours in medium containing a
combination of early-acting cytokines before transduction.17 We
Figure 2. Northern blot analysis of cells transduced by HIV-based (LT) and
MLV-based (RT) promoter traps and control MLV-based (R) and HIV-based (L)
vectors. Analysis was performed on 293T cells transduced with the indicated
vectors, before or after puromycin selection, and in representative puromycin-
resistant clones. Cells were transduced with matched vector doses yielding multicopy
integration (average of 10) per cell in the unselected cells (LT and RT), and average
single-copy integration in the selected populations (LT/RT selected), clones
(LT/RT cl), and in cells transduced by control vectors (L, R). The white arrow
indicates the LTR-driven antisense transcript of RT. Note that this transcript is
expressed to low extent because of the SIN modification and is better detected in
cells containing high numbers of vector integrants. The LT and RT lanes are
shown enlarged on the right and after a shorter exposure time for the RT lane to
better compare the hybridization pattern.
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Table 1. Mapping of integration sites
Int. ID
Chromosomal
band
Chromosomal
position, bp
Trapped gene
name/ref seq
gene ID Trapped gene description
Trap orientation
relative to gene
transcription
Distance
from
TSS, kb
Position within
transcription unit
Putative reporter
transcript
LT8 5q23.3 131666449 PDLIM4
NM_003687
LIM protein RIL (reversion-
induced LIM protein)
Sense 3 Intron 1 5 UTR fusion
LT1 15q22.2 57692244 BNIP2
NM_004330
BCL2/adenovirus E1B
19-kDa interacting
protein 2
Sense 5 Intron 1 5 UTR fusion
LTA4 17p1 3.2 4470248 UBE2G1
NM_003342
NM_182682
Ubiquitin-conjugating enzyme
E2G 1 (UBC7 homolog,
Caenorhabditis elegans)
Sense 5 Intron 1 In-frame fusion with
protein coding
mRNA
LT2 3p21.1 49785970 IHPK1
NM_153273
Inositol hexaphosphate
kinase 1
Sense 13 Intron 1 In-frame fusion with
protein coding
mRNA
LTA3 6p21.31 35685569 FKBP5
NM_004117
FK506 binding protein 5 Sense 16 Intron 1 or intron 3,
depending on
alternative promoter
In-frame fusion with
protein coding
mRNA
LT3 2q31.1 172195652 TLK1
NM_022644
Tousled-like kinase 1 Sense 24 Intron 1 In-frame fusion with
protein coding
mRNA
LTA10 10q26.11 12014001 C10orf46
NM_153810
Chromosome 10 open
reading frame 46
Sense 40 Intron 3 Fusion with an
untranslated splicing
isoform (C10orf46-
003)
LTA1 4q13.3 7230830 MOBKL1A
NM_173468
MOB1, Mps One Binder
kinase activator-like 1A
(yeast)
Antisense* 40* Intron 4* Fusion with natural
antisentisense
transcripts
LT10 17q23.3 62422791 CSH2
NM_022646
NM_022645
NM_022644
NM_020991
Chorionic
somatomammotropin
hormone 2
Antisense* 1.7* Exon 4* Fusion with natural
antisentisense
transcripts
LTA13 19q13.43 62696928 FLJ23233
NM_024691
Hypothetical protein
FLJ23233
Antisense* 16* Exon 5* Fusion with natural
antisentisense
transcripts
RT15.8 6p21.31 35745703 FKBP5
NM_004117
FK506 binding protein 5 Sense 
2 Upstream TSS,
downstream
predicted promoter†
Reporter transcript
without fusion to
endogenous mRNA
RT15.10 Xq21.1 75907912 DKFZp564K142
NM_032121
Implantation-associated
protein
Sense 
1.1 Upstream TSS,
downstream
predicted promoter†
Reporter transcript
without fusion with
endogenous mRNA
RT16.2 20q13.32 57911395 STK16
NM_003691
Serine/threonine kinase 16 Sense 
0.4 Upstream TSS,
downstream
predicted promoter†
Reporter transcript
without fusion with
endogenous mRNA
RT13 3q11.2 98965659 EST:
BM676895.1
NA Sense 0.1 Unknown EST fusion
RT5.6 19p13.3 2895544 ZNF77
NM_021217
Zinc finger protein 77 (pT1) Sense 0.2 Intron 1 In-frame fusion protein
RT6.1 16p13.3 679892 DKFZp434F054
NM_032259
Hypothetical protein
DKFZp434F054
Sense 0.5 Exon 1 or intron 2
depending on
alternative splicing
5 UTR fusion or in-
frame fusion protein
depending on
alternative splicing
RT25 20q13.33 62983740 GMEB2
NM_012384
Glucocorticoid modulatory
element binding protein 2
Sense 1 Intron 1 5 UTR fusion
RT7.6 19p13.3 1215668 UNIGENE ID:
Hs79706
Hs322473
Hs383245
NA Sense 1.5 Putative Exon 4 Fusion with
untranslated ESTs
RT12 22q12.3 34330975 MB
NM_203377
NM_005368
NM_203378
Myoglobin Sense 6 Intron 2 In-frame fusion protein
RT23 22q12.1 27383168 cB42E1.c22.1 NA Antisense* 17* Intron 1 Fusion with natural
antisentisense
transcripts?
Int. ID indicates integration ID; NA, not available.
*Relative to the known gene at the targeted locus. Because of the occurrence of natural antisense transcripts (NATs) for this gene, reporter expression may be driven by
these transcripts for which no information is available on TSS and intron/exon organization.
†Integration occurred upstream of the putative TSS of the targeted gene. First EF and eponine algorithms identified putative promoters in the region, some of which may
drive reporter expression.
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then treated the transduced cells with or without puromycin and
analyzed them by FACS for GFP expression and by clonogenic
assays to determine the frequency of puromycin-resistant hemato-
poietic colonies. In a first experiment, cells were transduced with
matched amounts of either vector to yield an average 20%
transduction frequency, to allow calculating trapping efficiency
from the assumption that vector-positive CFCs obtained in these
conditions contain a single vector copy. Consistently with the
results obtained in other cell types, the frequency of GFP-positive
cells in liquid culture (Figure 4B), and the frequency of puromycin-
resistant CFCs (Table 3) were significantly higher for cells
transduced by the MLV than the HIV trap. PCR analysis for
vector-specific sequences in hematopoietic colonies confirmed
similar frequency of integration by both vectors at the predicted
level (Table 3), showing that also in HPCs the MLV vector trapped
cellular promoters more efficiently than HIV. Furthermore, the
MLV trap was expressed to a higher extent both in the absence of
puromycin selection (not shown), or following selection (Figure 4C).
In a second experiment, we increased the HIV vector input and
found that cultures matching the frequency of reporter expression
Figure 3. Mapping of HIV-based (LT) and MLV-based (RT) promoter traps integration site in selected 293T cells. Puromycin-resistant cell populations and clones were
isolated from 293T cells transduced with LT or RT at very low vector input to ensure single-copy integration. Genomic DNA from selected bulk populations, 15 LT and 15 RT
clones was subjected to vector-specific LAM-PCR to retrieve the proviral-genomic junction. Ten LT and 10 RT integrations were unambiguously mapped after BLAST analysis
against the human genome database using the ENSEMBL search engine (September 2004 freeze). All characterized integrations are listed in Table 1. Three representative LT
(A-C) and RT (D-F) integrations are shown here in detail. The genomic region around the integration site (length in kb indicated on top) were obtained from the ENSEMBL
output and graphically simplified. Blue thick bars represent the selected chromosomal region. Query sequence from LAM-PCR product is placed in the middle of the genomic
interval and is represented by a red mark (BLAST hit) above or below the chromosomal bar depending on the provirus orientation. Because LAM-PCR products from the LT and
RT were obtained using the 3 LTR and 5 LTR as template, respectively, the orientation of the trapping cassette on the ENSEMBL output was opposite for LT and RT. For clarity,
proviral integration and the direction of transcription of the PuroR-GFP cassette are represented by a green arrow. Transcripts, protein alignments, and genomic annotations
were retrieved by searching different databases as displayed on the left side of each picture. Genes displayed above the blue bar are transcribed from left to right; genes
displayed below the bar are transcribed from right to left. (A) LTA4 integration on 17p13.2 landed in the first intron of the UBE2G1 gene before the first coding ATG. Promoters
(circles with arrows) are identified by algorithms Eponine and FirstEF (red marks). (B) LTA3 integration on 6p21.31 landed in the third intron of the FKBP5 gene before the first
coding ATG. Fusion transcript could be generated by 2 different promoters (circles with arrows) as identified by algorithms Eponine and FirstEF (red marks)19 and presence of a
CpG island (purple mark). The distance from the closest promoter is 16 kb. (C) LT1 integration on 15q22.2 landed into the first intron of the BNIP gene after the first noncoding
exon. Distance from transcription start site (TSS) was 5.5 kb. Reporter expression can be explained by a trap/5 untranslated region (UTR) fusion transcript. (D) Integration
RT16.2 on 20q13.32 landed into a CpG island, 350 base pair (bp) upstream of the putative transcription start site of the sintaxin 16 gene. Both First EF and Eponine algorithms
identified several putative promoter regions, one of which may drive reporter expression (circle with arrow). (E) RT25 integration on 20q13.33 landed into the first intron of the
GMEB2 gene after the first noncoding exon. Distance from TSS was1 kb. First EF and Eponine algorithms identified putative promoter regions (circle with arrow). (F) RT6.1
Integration on 16p13.3 landed into the DKFZp434F054 gene. Depending on the splicing, the trap can be fused to a 5 UTR exon. Alternatively, the same 5 UTR portion can be
spliced to generate an in-frame protein coding fusion transcript with the reporter. Distance from TSS was0.4 kb.
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obtained with the MLV trap had multicopy HIV integration in the
CFCs (Table 3). Interestingly, also in these latter transduction
conditions (low-copy MLV versus multicopy HIV trap integration),
puromycin-selected MLV-transduced cells expressed the reporter
gene to a higher extent than HIV-transduced cells (not shown).
Improved trap design increases trapping efficiency of HIV
vector by rescuing expression from promoter-distal integration
As discussed above, we ascribed the different trapping efficiency of
MLV and HIV traps to a different bias in integration site selection
within transcriptional units, in agreement with recently reported
studies.6-8 Promoter-proximal integrations, as observed more fre-
quently with MLV, will express the reporter protein up to 50% of
the time, depending on the orientation of insertion, and whether it
occurred upstream of the first coding ATG. Instead, integrations
occurring downstream of the first coding ATG, as observed more
frequently with HIV, will express the reporter protein in no more
than 1 in 6 times, due to the need for correct orientation (1 of 2) and
in-frame fusion (1 of 3). Furthermore, lengthy fusion transcript and
chimeric protein resulting from promoter-distal integration may be
unstable and further decrease the overall trapping efficiency.
To verify this explanation, we modified both vector traps to
make reporter expression insensitive to out-of-frame fusion and to
increase the stability of fusion mRNA. We inserted 3 tandem stop
codons in all reading frames followed by the IRES11 of the mouse
encephalomyocarditis virus between the SA site and the PuroR-
GFP transgene to terminate translation of the endogenous gene in
fusion transcripts and drive downstream reporter expression in
mRNAcap-independent way. We then added the wPRE13 between the
PuroR-GFP transgene and the polyA site to increase fusion tran-
script stability and enhance IRES-dependent expression, which has
been shown to be less efficient than that driven by the mRNAcap.21
We cloned the modified trapping cassette into the MLV and HIV
vector backbone to generate IRES.wPRE-RT and IRES.wPRE-LT
traps, respectively, and compared the performance of all traps in
293T cells (Figure 5A).
Remarkably, the modified IRES.wPRE-LT trap was signifi-
cantly more expressed than the original HIV trap (P  .01), with an
average increase in trapping efficiency of at least 3-fold. However,
no significant change was observed for the modified MLV trap
(Figure 5B). To assess the relative contribution of frame-
independence and increased RNA stability in the rescue of HIV
trap expression by the IRES.wPRE-LT construct, we generated
traps containing either the IRES or the wPRE element. Inclusion of
IRES alone was detrimental to reporter gene expression, as
expected from other studies22 and as clearly observed for the MLV
trap, which showed a statistically significant reduction in trapping
efficiency and GFP MFI in transduced cells. Notably, the HIV trap
did not show such an effect, suggesting that the detrimental effect
of IRES on gene expression level was balanced by an increase in
the proportion of transcripts leading to reporter expression. As
Figure 4. Transduction of primary hematopoietic progenitors by HIV-based (LT)
and MLV-based (RT) promoter traps. (A) FACS analysis of GFP expression in
murine hematopoietic progenitors transduced with matched amounts of the indicated
vector traps and analyzed 5 days after transduction. The frequency and MFI of
GFP-positive cells are indicated. Representative results of 2 experiments performed.
(B) FACS analysis of GFP expression in human cord blood CD34 cells stimulated for
36 hours with a cytokine cocktail, transduced with matched vector amounts yielding
low-copy ( 1) integration per cell, and analyzed after 1 week in liquid culture. The
percentage of GFP-positive cells is indicated. Representative results of 2 experi-
ments performed. (C) FACS analysis of GFP expression (histogram) of puromycin-
selected cells from the populations shown in panel B. UC indicates unselected cells.
Table 2. Transduction of PBMCs by HIV- and MLV-based traps
Donor
HIV trap, LT†‡ MLV trap, RT†‡
Expression
Integration,
CpC
% trapping
efficiency,
expr/integr
Expression
Integration,
CpC
% Trapping
efficiency,
expr/integr% GFP MFI* % GFP MFI*
A
106 TU/mL 1.0 16.0 0.12 8.3 0.6 19.1 ND ND
107 TU/mL 1.7 13.8 0.20 8.5 1.5 19.2 0.04 37.5
B
106 TU/mL 2.8 12.6 0.32 8.7 0.8 14.1 0.02 37.7
107 TU/mL 5.5 11.5 0.69 8.0 3.3 15.0 0.09 36.6
TU indicates 293T transducing units; ND, not determined.
*Mean fluorescence intensity is measured after puromycin selection.
†Paired Student t test calculated on MFI of GFP-positive cells (% GFP), with P  .05.
‡Unpaired Student t test calculated on trapping efficiency, with P  .01.
Table 3. CFC assays of transduced CD34 cells
Experiment
Vector-positive
CFCs, %
Puromycin-resistant
CFCs, %
Trapping efficiency,
%
LT exp 1 23 0.5 2
RT exp 1 18 3.3 18
LT exp 2 96 7.1  7*
RT exp 2 23 4.9 21
Colony-forming cell (CFC) assays of the same cells shown in Figure 4B (exp1)
and from a different experiment that used a higher input of LT vector (exp2), plated in
semisolid medium with or without puromycin. The frequency of vector- positive CFCs
was determined by PCR performed on unselected CFCs. The frequency of puromycin-
resistant CFCs was calculated from the ratio between CFCs grown in medium with
and without puromycin. The frequency of promoter trapping was calculated as the
ratio between puromycin-resistant CFCs and vector-positive CFCs.
*In the presence of multicopy vector integration, the frequency of trapping
(trapping efficiency) is overestimated.
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expected, inclusion of the wPRE alone significantly enhanced
expression of both MLV and HIV traps, however, maintaining
significant differences in trapping efficiency and GFP MFI between
the 2 vector types.
In conclusion, the differential effect of IRES on HIV versus
MLV trap expression indicated that HIV integrations were much
more frame-dependent for expression than MLV; ie, they occurred
within transcribed genes but downstream of the first coding ATG.
However, the frame-independence of reporter expression by MLV
integrations strongly supported our previous conclusion that they
occurred in close proximity to promoters. Thus, the differences in
trapping efficiency observed for the original constructs (RT and LT)
were due to a specific bias of MLV in integration site selection, ie,
close proximity to active promoters, and not to a more frequent
integration into transcribed genes or to vector backbone-dependent
effects on reporter expression.
Discussion
Here we used a promoter trap built into HIV and MLV vectors to
evaluate integration site selection in the target cell genome. We
found a highly significant difference in trapping efficiency between
the 2 vectors and showed by several lines of evidence that this
effect was dependent on a different integration pattern of the 2
viruses within transcribed genes.
Our study provides direct, functional evidence that MLV
vectors preferentially integrate close to highly active promoters in
the different cell types tested and can efficiently exploit them for
proviral expression. Such results are consistent with a recent study
that analyzed 903 MLV integration sites by PCR-mediated cloning
and reported preferential occurrence within 5 kb from transcrip-
tion start sites of cellular genes (20% of the sites), and within  1
kb from CpG islands (16% of the sites).7 Notably, with the
promoter trapping approach used here, we were able to screen
several hundred thousand integrations in different target cell types,
including primary hematopoietic cells, for both MLV and HIV
vectors. By using a functional readout, our analysis did not rely on
the sometimes uncertain “in silico” identification of genes and
transcription regulatory elements and on our current knowledge of
the overall extent of genome transcription,23 and avoided possible
biases as a result of the vector-genome junction retrieval proce-
dures. Thus, our results confirm and extend the conclusions of the
study by Wu et al.7
Remarkably, from 1 of 7 up to 1 of 3 MLV integrations resulted
in reporter gene expression. Because only integrations occurring
downstream from a promoter and with the proper orientation will
express the reporter, the MLV bias for integration proximal to
active promoters may even be higher than previously estimated.7
This surprisingly high trapping efficiency may be dependent on
specific experimental conditions, such as strong synchronous T-cell
receptor (TCR) activation in PBMCs, a low vector input, and the
inclusion of the wPRE element in the trap that enhances reporter
gene expression by stabilizing the transcript.13 Target cell stimula-
tion may increase the number or the avidity of the preferred
genomic sites available to a low vector input and highlight a
nonrandom saturable integration behavior that tethers the viral
preintegration complex to transcriptionally active promoters. In
agreement with this hypothesis, we noticed that the MLV promoter
trapping efficiency decreased by increasing the vector input in the
cell lines tested (data not shown).
In addition, by comparing MLV and HIV integration in
similarly infected cells, we consistently found that the MLV trap
was expressed to a slightly but significantly higher level than the
HIV trap, suggesting preferential MLV integration into a subset of
more actively transcribed genes. However, we cannot exclude that
the different integration pattern of MLV and HIV within transcrip-
tion units may play a role in this finding, given the complex
interplay of factors affecting reporter protein expression, including
mRNA and protein stability. Notably, addition of the wPRE
element enhanced expression of both MLV and HIV traps while
maintaining the difference in GFP MFI between the 2 vector types.
A comparative analysis of gene expression at the trapped locus and
at the wild-type allele within isolated clones would clarify these
issues. If verified, the finding of MLV integration into a subset of
more actively transcribed genes will highlight the specificity of the
rules governing integration site selection by different integrating
viruses, making a strong case for virus-specific interactions with
cellular proteins tethering the integration complex to selected gene
sets.24 Targeting of a highly transcribed gene subset by MLV may
reflect tethering of its integration complex by cellular components
recruited at highly active or induced (growth-responsive) promoters.
Promoter targeting may have evolved in the parental retrovi-
ruses to provide a fraction of their progeny with a supplementary
cellular promoter, less susceptible to silencing by genome surveil-
lance mechanisms than the one embedded in the LTR,25 and
possibly enhancing env gene expression by alternative splicing.
The proximity and functional relationship frequently established
between MLV proviruses and flanking cellular promoters in our
study indicate that integration of enhancer-rich wild-type MLV
LTR is likely to up-regulate transcription from cellular promoters
and, depending on proviral position and orientation, overexpress
Figure 5. Trapping efficiency of IRES/wPRE modified HIV-based (LT) and
MLV-based (RT) promoter traps. (A) Schematic of the modified trapping cassettes;
legend as in Figure 1A. IRES indicates internal ribosome entry site; wPRE,
woodchuck post-transcriptional regulatory element. (B) Histogram showing the
trapping efficiency of the indicated vector traps. Bars indicate the percentage of
integrations that express the reporter gene (trapping efficiency, mean SEM, n  4).
Statistical significance by Student t test of the difference between the indicated
experimental groups is shown. For each trap, the mean fluorescence intensity (MFI)
of GFP-positive cells (calculated from cell cultures with frequency of GFP cells
 15%) is indicated (mean, n  2).
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the cognate genes, including proto-oncogenes. The observed MLV
integration behavior thus explains the well-known oncogenicity of
wild-type gamma-retroviruses26,27 and underscores the risk of
insertional mutagenesis by MLV-derived vectors.2,3,28
HIV- and HIV-derived vectors have been reported to integrate
more frequently within transcribed genes than outside of them.6
However, since they insert throughout the transcriptional unit
without showing a bias for promoter-proximal integration7 (our
data in “Results”), the promoter trapping efficiency of HIV traps
was much lower than that observed for MLV traps. When we
modified the trap design to make reporter expression potentially
insensitive to promoter-distal integration, HIV traps expressed the
reporter in up to 1 of 5 integrations. This figure is consistent with a
strongly favored HIV integration into active genes, if one considers
that trap expression occurs only upon integration in the proper
orientation, that expression of IRES-containing traps is suboptimal,
and that only a fraction of the genome is transcribed in target cells.
Preferential intragenic integration of HIV vectors was very recently
reported in primary hematopoietic cells,29,30 and integration inten-
sity was shown to positively correlate with transcriptional intensity
in one study.29 Preferential insertion throughout transcriptionally
permissive chromatin may benefit the lentivirus lifestyle, which
spread horizontally in the cognate host species, target interphase
chromatin crossing the nucleopore, and express their own transcrip-
tion regulators. Whether this behavior of the parental virus,
together with the advanced vector engineering that fully inactivates
the HIV LTR, provide a safer integrating tool for gene therapy
remains, however, to be directly demonstrated.
Promoter trapping efficiency may provide a convenient readout
to test whether genetic engineering of the vector framework, ie, the
incorporation of chromatin insulators, can disrupt transcriptional
interactions with the flanking genome. Furthermore, this approach
can be used to compare integration site selection among different
target cell types and between cells transduced under different
growth conditions. In addition, the improved HIV traps described
in this study provide powerful new tools to perform gene expres-
sion studies in target cells which are poorly transfected by
MLV-based vectors or other means, such as primary and quiescent
cells, stem cells, and embryos.
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